Fox Run Management L.L.C. Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Fox Run Management L.L.C. purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,421 shares of the specialty pharmaceutical company’s stock, valued at approximately $544,000.

Several other institutional investors and hedge funds also recently bought and sold shares of JAZZ. CIBC Asset Management Inc grew its position in Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after acquiring an additional 97 shares during the last quarter. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the period. Jones Financial Companies Lllp lifted its holdings in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares in the last quarter. Waterfront Wealth Inc. grew its stake in Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after acquiring an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after acquiring an additional 149 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $187.71.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last 90 days. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Trading Up 2.3 %

NASDAQ JAZZ opened at $142.02 on Tuesday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The firm has a 50 day simple moving average of $131.79 and a 200-day simple moving average of $122.03. The firm has a market cap of $8.63 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.